Japanese pharmaceutical and life science companies, facing domestic constraints on growth and profits, need to focus on innovation and expanding into emerging markets such as China and India, according to statements by leading industry officials at concurrent meetings of in-Pharma Japan and Interphex Japan in Tokyo. MSD President Tony Alvarez stressed the need to tie innovation to the customer, and Fumiyoshi Sakai of Credit Suisse Securities, Japan, urged companies to invest in markets where economic growth is substantially higher than health care expenditures.

Full Story:
BioSpectrum Asia

Related Summaries